Your browser doesn't support javascript.
loading
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
Ilagan-Ying, Ysabel C; Banini, Bubu A; Do, Albert; Lam, Robert; Lim, Joseph K.
Afiliação
  • Ilagan-Ying YC; Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
  • Banini BA; Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
  • Do A; Yale Liver Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
  • Lam R; Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
  • Lim JK; Yale Liver Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Curr Gastroenterol Rep ; 25(10): 213-224, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37768417
PURPOSE OF REVIEW: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease affecting 30% of the global population. In this article, we summarize current expert guidelines, review clinical practice implications, and provide insight into the utility of non-invasive tests (NITs). RECENT FINDINGS: The burden of MASLD is growing with the obesity epidemic, yet disease awareness and diagnosis is low. Patients can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which can advance to liver fibrosis, cirrhosis, hepatic decompensation, and liver cancer. NITs help identify high-risk patients who may benefit from specialty referral and MASH-directed therapy. Global societies offer various recommendations for the screening and diagnosis of MASLD utilizing evidence-based, widely accessible methods such as serum indices, NITs, and liver biopsy. Several targeted steatotic liver disease (SLD) screening tools and novel therapies are under development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Curr Gastroenterol Rep Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Curr Gastroenterol Rep Ano de publicação: 2023 Tipo de documento: Article